HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David A. Fullerton James Jaggers Frederick L. Grover Robert C. McIntyre, Jr. Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fullerton, D. A. Articles by McIntyre, R. C. Search for Related Content PubMed PubMed Citation Articles by Fullerton, D. A. Articles by McIntyre, R. C., Jr.

J Thorac Cardiovasc Surg 1997;113:363-370
© 1997 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

EFFECTIVE CONTROL OF REFRACTORY PULMONARY HYPERTENSION AFTER CARDIAC OPERATIONS

Supported by National Institutes of Health grant R29HL49398.

Received for publication July 3, 1996; revisions requested August 9, 1996; revisions received Sept. 24, 1996; accepted for publication Sept 24, 1996. Address for reprints: David A. Fullerton, MD, Cardiothoracic Surgery, Northwestern University Medical School, Wesley Pavilion Suite 1030, 251 East Chicago Ave., Chicago, IL 60611-2614.

Abstract

Objectives: Inhaled nitric oxide is a promising therapy to control pulmonary hypertension. However, pulmonary hypertension caused by valvular heart disease is often refractory to inhaled nitric oxide. The objective of this study was to determine whether the combination of inhaled nitric oxide plus dipyridamole will cause a response in patients with pulmonary hypertension undergoing cardiac operations who had not responded to inhaled nitric oxide alone. Methods: Responses in 10 patients (62 ± 7 years) with pulmonary hypertension caused by aortic or mitral valvular disease (mean pulmonary artery pressure, 30 mm Hg) were studied in the operating room after valve replacement. The effect of inhaled nitric oxide alone (40 ppm) on pulmonary vascular resistance, mean pulmonary artery pressure, cardiac output, and mean arterial pressure was determined. Inhaled nitric oxide administration was then stopped and patients were given dipyridamole (0.2 mg/kg intravenously); the effect of inhaled nitric oxide plus dipyridamole was then examined. Results: Dipyridamole effected a response in patients who had not responded to nitric oxide. Pulmonary vascular resistance and mean pulmonary artery pressure were significantly reduced and cardiac output was increased without change in mean arterial pressure. Conclusions: Patients with refractory pulmonary hypertension in whom inhaled nitric oxide alone fails to cause a response may respond to combined therapy of inhaled nitric oxide plus dipyridamole. This therapy may be particularly valuable in patients with dysfunction of the right side of the heart as a result of pulmonary hypertension because of its effective lowering of right ventricular afterload.

This article has been cited by other articles:

				T. S. Maxey, L. G. Fernandez, T. B. Reece, W. B. Keeling, I. L. Kron, and V. E. Laubach Endothelial Nitric Oxide Synthase is Essential for Postpneumonectomy Compensatory Vasodilation Ann. Thorac. Surg., April 1, 2006; 81(4): 1234 - 1238. [Abstract] [Full Text] [PDF]

				G. Ramakrishna, J. Sprung, B. S. Ravi, K. Chandrasekaran, and M. D. McGoon Impact of Pulmonary Hypertension on the Outcomes of Noncardiac Surgery: Predictors of Perioperative Morbidity and Mortality J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1691 - 1699. [Abstract] [Full Text] [PDF]

				Y. Saiki, Y. Nitta, Y. Tsuru, and K. Tabayashi Successful weaning from inhaled nitric oxide using dipyridamole Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 837 - 839. [Abstract] [Full Text] [PDF]

				D. N. Cornfield, E. R. Resnik, J. M. Herron, O. Reinhartz, and J. R. Fineman Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease Am J Physiol Lung Cell Mol Physiol, December 1, 2002; 283(6): L1210 - L1219. [Abstract] [Full Text] [PDF]

				T. S. Maxey, C. D. Smith, J. A. Kern, C. G. Tribble, D. R. Jones, I. L. Kron, and I. K. Crosby Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients Ann. Thorac. Surg., February 1, 2002; 73(2): 529 - 533. [Abstract] [Full Text] [PDF]

				D. C. Stuesse, G. D. Giraud, A. A. Vlessis, A. Starr, and D. D. Trunkey Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 371 - 377. [Abstract] [Full Text] [PDF]

				R. F. Lodato Viagra for Impotence of Pulmonary Vasodilator Therapy? Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 312 - 313. [Full Text]

				G. Barba, M. J. Mullen, A. Donald, and R. J. MacAllister Determinants of the Response of Human Blood Vessels to Nitric Oxide Donors In Vivo J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1662 - 1668. [Abstract] [Full Text]

				J. W. ZIEGLER, D. D. IVY, J. W. WIGGINS, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN Effects of Dipyridamole and Inhaled Nitric Oxide in Pediatric Patients with Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1388 - 1395. [Abstract] [Full Text] [PDF]

				D. R. Meldrum, B. D. Shames, X. Meng, D. A. Fullerton, R. C. McIntyre Jr, F. L. Grover, and A. H. Harken Nitric oxide downregulates lung macrophage inflammatory cytokine production Ann. Thorac. Surg., August 1, 1998; 66(2): 313 - 317. [Abstract] [Full Text] [PDF]

				D. D. Ivy, J. P. Kinsella, J. W. Ziegler, and S. H. Abman Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 875 - 882. [Abstract] [Full Text] [PDF]

				Nitric Oxide Useful for Pulmonary Hypertension Journal Watch Cardiology, March 25, 1997; 1997(325): 9 - 9. [Full Text]